A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
08/04/2022at 09:44

Danish Medicines Council considers fast-track scheme

When the Danish Medicines Council meets with representatives from the Danish Regions in April, the possibility of implementing a fast-track scheme in the country may be on the agenda.
Photo: Mikkel Berg Pedersen/JPA
By Mikkel aabenhus hemmingsen, translated by catherine brett

Since it was established in 2017, the Danish Medicines Council has come under fire for its long case processing times. Now, however, the council may be doing something about it.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Column: This is how the Danish Medicines Council should strengthen its application process

    For subscribers

  • Photo: Stine Rasmussen/Ritzau Scanpix

    Danish Medicines Council releases recommendations – mixed bag for Sanofi and BMS

    For subscribers

  • Reaffirming earlier decisions, the Danish Medicines Council has deemed Janssen's nasal spray against depression unfit for Danish patients | Photo: Sisse Dupont/INDBLIK

    Janssen puzzled by Denmark's refusal of antidepressant nasal spray

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

GN’s proposed board member, Klaus Holse, runs in the same board circles as the CEO of William Demant Invest – but GN says the pick is unrelated to ”any conceivable or inconceivable acquisition.”
  • Is William Demant Invest seeking hostile takeover of GN? Three scenarios in play
  • Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Further reading

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

When GN Group’s chair retires following the company’s next AGM, it could pave the way for a large consolidation within the Danish hearing aid market, an analyst says.

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Foto: Stine Rasmussen/Ritzau Scanpix
Regulation

Denmark recommends three drugs

New treatments for arthritis, esophageal cancer, and depression will be available for Danish patients after the Danish Medicines Council has made new recommendations.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Application Manager

  • Principal Laboratory Technologist

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Head of International Sales

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Clinical Operational Associate

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Experienced Patent Counsel

  • Commercial Director

See all jobs

Jobs

  • Application Manager

  • Principal Laboratory Technologist

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Head of International Sales

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Clinical Operational Associate

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Experienced Patent Counsel

  • Commercial Director

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge